SKP2 and prostate carcinoma: Studies have shown that equol inhibits Skp2-mediated degradation of androgen receptor (AR), thereby suppressing the growth of prostate cancer through S-phase kinase-associated protein 2(Skp2)-mediated AR degradation [99], as well as specifically binding to 5α-dihydrotestosterone to prevent its binding with AR [25].